Clinical trial NCT00600210 - References

Cervical Cancer — Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer

Citation(s)

•   Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF, Brown LF
  Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest. 1996 Jun;74(6):1105-15.
•   Abulafia O, Triest WE, Sherer DM, Hansen CC, Ghezzi F
  Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma. Obstet Gynecol. 1995 Oct;86(4 Pt 1):479-85.
•   Abulafia O, Triest WE, Sherer DM
  Angiogenesis in malignancies of the female genital tract. Gynecol Oncol. 1999 Feb;72(2):220-31. Review.
•   Abulafia O, Triest WE, Sherer DM
  Angiogenesis in primary and metastatic epithelial ovarian carcinoma. Am J Obstet Gynecol. 1997 Sep;177(3):541-7.
•   Bachtiary B, Selzer E, Knocke TH, Pötter R, Obermair A
  Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival. Cancer Lett. 2002 May 28;179(2):197-203.
•   Bergers G, Benjamin LE
  Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003 Jun;3(6):401-10. Review.
•   Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR, Smith SK
  Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst. 1995 Apr 5;87(7):506-16.
•   Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ
  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol. 1995 Jan;26(1):86-91.
•   Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR
  Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol. 1993 Nov;143(5):1255-62.
•   Carmeliet P, Jain RK
  Angiogenesis in cancer and other diseases. Nature. 2000 Sep 14;407(6801):249-57. Review.
•   Chen CA, Cheng WF, Lee CN, Chen TM, Kung CC, Hsieh FJ, Hsieh CY
  Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol Oncol. 1999 Aug;74(2):235-40.
•   Cheng WF, Chen CA, Lee CN, Chen TM, Hsieh FJ, Hsieh CY
  Vascular endothelial growth factor in cervical carcinoma. Obstet Gynecol. 1999 May;93(5 Pt 1):761-5.
•   Cheng WF, Chen CA, Lee CN, Wei LH, Hsieh FJ, Hsieh CY
  Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstet Gynecol. 2000 Nov;96(5 Pt 1):721-6.
•   Cho NH, Kim YB, Park TK, Kim GE, Park K, Song KJ
  P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma. Gynecol Oncol. 2003 Nov;91(2):346-53.
•   Finlay MH, Ackerman I, Tirona RG, Hamilton P, Barbera L, Thomas G
  Use of CT simulation for treatment of cervical cancer to assess the adequacy of lymph node coverage of conventional pelvic fields based on bony landmarks. Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):205-9. Epub 2005 Sep 29.
•   Gaffney DK, Haslam D, Tsodikov A, Hammond E, Seaman J, Holden J, Lee RJ, Zempolich K, Dodson M
  Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):922-8.
•   Gasparini G
  Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Crit Rev Oncol Hematol. 2001 Feb;37(2):97-114. Review.
•   Guidi AJ, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF, Brown LF
  Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst. 1995 Aug 16;87(16):1237-45.
•   Guidi AJ, Abu-Jawdeh G, Tognazzi K, Dvorak HF, Brown LF
  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer. 1996 Aug 1;78(3):454-60.
•   Higgins RV, Naumann WR, Hall JB, Haake M
  Concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer. Gynecol Oncol. 2003 Jun;89(3):499-503.
•   Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ
  Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol. 1995 Jul;147(1):33-41.
•   Ishiwata I, Ishiwata C, Soma M, Ono I, Nakaguchi T, Ishikawa H
  Tumor angiogenic activity of gynecologic tumor cell lines on the chorioallantoic membrane. Gynecol Oncol. 1988 Jan;29(1):87-93.
•   Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ
  Cancer statistics, 2005. CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30. Erratum in: CA Cancer J Clin. 2005 Jul-Aug;55(4):259.
•   Kersemaekers AM, Fleuren GJ, Kenter GG, Van den Broek LJ, Uljee SM, Hermans J, Van de Vijver MJ
  Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res. 1999 Mar;5(3):577-86.
•   Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, Walker JL, Gersell D
  Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999 Apr 15;340(15):1154-61. Erratum in: N Engl J Med 1999 Aug 26;341(9):708.
•   Kim JW, Kim YT, Kim DK, Song CH, Lee JW
  Expression of epidermal growth factor receptor in carcinoma of the cervix. Gynecol Oncol. 1996 Feb;60(2):283-7.
•   Kitayama H, Maeshima Y, Takazawa Y, Yamamoto Y, Wu Y, Ichinose K, Hirokoshi K, Sugiyama H, Yamasaki Y, Makino H
  Regulation of angiogenic factors in angiotensin II infusion model in association with tubulointerstitial injuries. Am J Hypertens. 2006 Jul;19(7):718-27.
•   Kristensen GB, Holm R, Abeler VM, Tropé CG
  Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer. 1996 Aug 1;78(3):433-40.
•   Lanciano R, Calkins A, Bundy BN, Parham G, Lucci JA 3rd, Moore DH, Monk BJ, O'Connor DM
  Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. J Clin Oncol. 2005 Nov 20;23(33):8289-95. Epub 2005 Oct 17.
•   Lee IJ, Park KR, Lee KK, Song JS, Lee KG, Lee JY, Cha DS, Choi HI, Kim DH, Deung YK
  Prognostic value of vascular endothelial growth factor in Stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):768-79.
•   Lokich J, Anderson N
  Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol. 1998 Jan;9(1):13-21. Review. Erratum in: Ann Oncol 1998 Mar;9(3):341.
•   Loncaster JA, Cooper RA, Logue JP, Davidson SE, Hunter RD, West CM
  Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer. 2000 Sep;83(5):620-5.
•   Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA
  Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet. 1992 Jul 18;340(8812):145-6.
•   Mathur RS, Mathur SP
  Vascular endothelial growth factor (VEGF) up-regulates epidermal growth factor receptor (EGF-R) in cervical cancer in vitro: this action is mediated through HPV-E6 in HPV-positive cancers. Gynecol Oncol. 2005 Apr;97(1):206-13.
•   Nagai N, Oshita T, Fujii T, Kioka H, Katsube Y, Ohama K
  Prospective analysis of DNA ploidy, proliferative index and epidermal growth factor receptor as prognostic factors for pretreated uterine cancer. Oncol Rep. 2000 May-Jun;7(3):551-9.
•   Nakanishi Y, Kodama J, Yoshinouchi M, Tokumo K, Kamimura S, Okuda H, Kudo T
  The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer. Int J Gynecol Pathol. 1997 Jul;16(3):256-62.
•   Ngan HY, Cheung AN, Liu SS, Cheng DK, Ng TY, Wong LC
  Abnormal expression of epidermal growth factor receptor and c-erbB2 in squamous cell carcinoma of the cervix: correlation with human papillomavirus and prognosis. Tumour Biol. 2001 May-Jun;22(3):176-83.
•   Parkin DM, Bray F, Ferlay J, Pisani P
  Global cancer statistics, 2002. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108.
•   Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S
  Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999 Apr 15;340(15):1144-53. Erratum in: N Engl J Med 1999 Aug 26;341(9):708.
•   Scambia G, Ferrandina G, Distefano M, D'Agostino G, Benedetti-Panici P, Mancuso S
  Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer. Cancer Lett. 1998 Jan 30;123(2):135-9.
•   Skomedal H, Kristensen GB, Lie AK, Holm R
  Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas. Gynecol Oncol. 1999 May;73(2):223-8.
•   Smith-McCune KK, Weidner N
  Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res. 1994 Feb 1;54(3):800-4.
•   Soufla G, Sifakis S, Baritaki S, Zafiropoulos A, Koumantakis E, Spandidos DA
  VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. Cancer Lett. 2005 Apr 18;221(1):105-18.
•   Tjalma W, Weyler J, Weyn B, Van Marck E, Van Daele A, Van Dam P, Goovaerts G, Buytaert P
  The association between vascular endothelial growth factor, microvessel density and clinicopathological features in invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol. 2000 Oct;92(2):251-7.
•   Tokumo K, Kodama J, Seki N, Nakanishi Y, Miyagi Y, Kamimura S, Yoshinouchi M, Okuda H, Kudo T
  Different angiogenic pathways in human cervical cancers. Gynecol Oncol. 1998 Jan;68(1):38-44.
•   Wild R, Dings RP, Subramanian I, Ramakrishnan S
  Carboplatin selectively induces the VEGF stress response in endothelial cells: Potentiation of antitumor activity by combination treatment with antibody to VEGF. Int J Cancer. 2004 Jun 20;110(3):343-51.
•   Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY
  Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005 Nov 1;23(31):8136-9.
•   Xu L, Xie K, Mukaida N, Matsushima K, Fidler IJ
  Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells. Cancer Res. 1999 Nov 15;59(22):5822-9.

AVF3963s Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer

Details for clinical trial NCT00600210